Patients with previously untreated metastatic colorectal cancer (CRC) who received a triplet combination chemotherapy plus bevacizumab (Avastin) had a 25% lower risk of progression than those treated with a dual combination chemotherapy plus bevacizumab ( N. Engl. J. Med. 2014;371:1609–18 and J. Clin. Oncol. 2015;33 (suppl. 3; abstr. 657, http://meetinglibrary.asco.org/content/139397-158 ). Researchers presented these findings of the Triplet plus Bevacizumab (TRIBE) study at the 2015 Gastrointestinal Cancers Symposium in January. The median progression-free survival (PFS) was 12.1 months in the leucovorin, fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab arm, compared with 9.7 months in the fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab control arm ( p = 0.003). The rate of response, 65%, was also higher in the triplet therapy arm than the control arm’s 53% ( p = 0.006). But this doesn’t mean that this regimen should now be the new standard of care, said Axel Grothey, M.D., oncologist at the Mayo Clinic in Rochester, Minn., who was not involved in the study.
No takes yet. Share an insight, caveat, or question.
Anna Azvolinsky (2015) studied this question.